The Biochemical Evidence Layer: Metabolomics for AI-Powered Drug Development

Artificial intelligence has fundamentally changed how the drug development industry identifies targets, prioritizes candidates, and designs programs. Yet for all its predictive power, most AI platforms are built primarily on genomic, proteomic, and literature-mined datasets. These data layers, while informative,  describe biological potential but not biological reality. This results in a capability gap that many programs don’t realize they have, where predictions are technically sophisticated but functionally incomplete. Metabolomics closes that gap.

As the downstream readout of gene expression, protein activity, and environmental interaction, the metabolome captures biological state with a directness no other omics layer can match. Where genomics and transcriptomics describe what a cell is capable of doing, metabolomics reveals what it is actually doing. This technology is uniquely positioned to provide the real-time functional context that AI models need to move from promising prediction to phenotypically grounded decision. If your program is not integrating this data stream, it is moving with speed but not with full precision.

This webinar will explore how metabolomics functions as the biochemical evidence layer AI-driven programs are missing. From target confirmation and mechanism of action elucidation to safety and toxicity detection and patient stratification, metabolomics transforms a promising computational prediction into a development decision grounded in real biology.

Attendees will see how metabolomics has delivered concrete results across published drug development programs, giving teams the functional evidence needed to make critical go/no-go decisions with greater confidence, speed, and efficiency. Join us to explore these documented outcomes and make the case for why metabolomics belongs in every AI-driven program.

In this webinar, you will learn about:

• The Data Your AI Model Is Missing – Understand why most AI drug discovery platforms are trained on incomplete biology, and how adding metabolomics as a functional data stream sharpens predictions toward phenotype, drug efficacy, and safety.
• Metabolite-based Mechanism of Action Confirmation – Discover how metabolomics resolves an uncertain compound mechanism and confirms the true biochemical target, turning a stalled program into actionable therapeutic opportunities before further resources are committed.
• Metabolite-based Safety & Toxicity Detection – Learn how the pretreatment metabolome surfaces early toxicity signals that and stratifies patient risk before treatment begins, well-informed go/no-go decisions and helping avoid costly late-stage attrition.
• The Metabolon Advantage – Learn how Metabolon’s coverage, reproducibility, and interpretation services make case studies like these possible, and the rationale for building metabolomics into your program from the start.